212 related articles for article (PubMed ID: 27911861)
1. Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis.
Zhu H; Luo H; Zhu X; Hu X; Zheng L; Zhu X
Oncotarget; 2017 Jan; 8(1):1628-1640. PubMed ID: 27911861
[TBL] [Abstract][Full Text] [Related]
2. Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer.
Lin Y; Liu F; Fan Y; Qian X; Lang R; Gu F; Gu J; Fu L
Int J Clin Exp Pathol; 2015; 8(7):8028-37. PubMed ID: 26339369
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of metabolic enzyme pyruvate kinase M2 in breast cancer: A meta-analysis.
Yang Y; Wu K; Liu Y; Shi L; Tao K; Wang G
Medicine (Baltimore); 2017 Nov; 96(46):e8690. PubMed ID: 29145305
[TBL] [Abstract][Full Text] [Related]
4. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of pyruvate kinase M2 predicts a poor prognosis for patients with osteosarcoma.
Liu ZX; Hong L; Fang SQ; Tan GH; Huang PG; Zeng Z; Xia X; Wang XX
Tumour Biol; 2016 Nov; 37(11):14923-14928. PubMed ID: 27644251
[TBL] [Abstract][Full Text] [Related]
6. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway.
Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097
[TBL] [Abstract][Full Text] [Related]
7. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
[TBL] [Abstract][Full Text] [Related]
8. Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies.
Wu J; Hu L; Chen M; Cao W; Chen H; He T
Onco Targets Ther; 2016; 9():4277-88. PubMed ID: 27478385
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis.
Liu Y; Wu K; Shi L; Xiang F; Tao K; Wang G
PLoS One; 2016; 11(11):e0166230. PubMed ID: 27824926
[TBL] [Abstract][Full Text] [Related]
10. Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) Expression Is Associated with Overall Survival in Pancreatic Ductal Adenocarcinoma.
Lockney NA; Zhang M; Lu Y; Sopha SC; Washington MK; Merchant N; Zhao Z; Shyr Y; Chakravarthy AB; Xia F
J Gastrointest Cancer; 2015 Dec; 46(4):390-8. PubMed ID: 26385349
[TBL] [Abstract][Full Text] [Related]
11. Pyruvate kinase M2 is highly correlated with the differentiation and the prognosis of esophageal squamous cell cancer.
Zhan C; Shi Y; Lu C; Wang Q
Dis Esophagus; 2013; 26(7):746-53. PubMed ID: 23317289
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical significance of pyruvate kinase M2 in breast cancer: A protocol for meta-analysis and bioinformatics validation analysis.
Li H; Yan M; Wu X; Wang Y; Huang L
Medicine (Baltimore); 2021 May; 100(18):e25545. PubMed ID: 33950928
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of metabolic markers PKM2 and LDH5 correlates with aggressive clinicopathological features and adverse patient prognosis in tongue cancer.
Yuan C; Li Z; Wang Y; Qi B; Zhang W; Ye J; Wu H; Jiang H; Song LN; Yang J; Cheng J
Histopathology; 2014 Nov; 65(5):595-605. PubMed ID: 24762230
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer.
Lu W; Cao Y; Zhang Y; Li S; Gao J; Wang XA; Mu J; Hu YP; Jiang L; Dong P; Gong W; Liu Y
Sci Rep; 2016 Jun; 6():26351. PubMed ID: 27283076
[TBL] [Abstract][Full Text] [Related]
15. Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value.
Cui R; Shi XY
Int J Clin Exp Pathol; 2015; 8(9):11393-9. PubMed ID: 26617865
[TBL] [Abstract][Full Text] [Related]
16. High expression of PKM2 as a poor prognosis indicator is associated with radiation resistance in cervical cancer.
Zhao Y; Shen L; Chen X; Qian Y; Zhou Q; Wang Y; Li K; Liu M; Zhang S; Huang X
Histol Histopathol; 2015 Nov; 30(11):1313-20. PubMed ID: 25936600
[TBL] [Abstract][Full Text] [Related]
17. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
Chao TK; Huang TS; Liao YP; Huang RL; Su PH; Shen HY; Lai HC; Wang YC
PLoS One; 2017; 12(7):e0182166. PubMed ID: 28753677
[TBL] [Abstract][Full Text] [Related]
18.
Lai YJ; Chou YC; Lin YJ; Yu MH; Ou YC; Chu PW; Wu CC; Wang YC; Chao TK
Int J Environ Res Public Health; 2019 Nov; 16(23):. PubMed ID: 31756939
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer.
Lim JY; Yoon SO; Seol SY; Hong SW; Kim JW; Choi SH; Cho JY
World J Gastroenterol; 2012 Aug; 18(30):4037-43. PubMed ID: 22912555
[TBL] [Abstract][Full Text] [Related]
20. Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture.
Dong T; Yan Y; Chai H; Chen S; Xiong X; Sun D; Yu Y; Deng L; Cheng F
Biomed Pharmacother; 2015 Feb; 69():277-84. PubMed ID: 25661370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
